To evaluate the development of immune-related adverse events (irAEs), especially ILD associates with treatment efficacy by immune-checkpoint inhibitors
Latest Information Update: 15 Feb 2020
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 15 Feb 2020 New trial record